Medicine and Dentistry
Colorectal Carcinoma
100%
Malignant Neoplasm
71%
Neoplasm
70%
Rectum Cancer
48%
Disease
40%
Metastatic Colorectal Cancer
33%
Durvalumab
31%
Overall Survival
25%
Primary Health Care
24%
DNA Mismatch Repair
23%
Hazard Ratio
21%
Histopathology
21%
Secondary Care
20%
Health Service
19%
Colorectal Tumor
19%
Biological Marker
19%
Carcinogenesis
17%
Lymph Node
15%
Cancer Radiotherapy
15%
Shared Care
15%
Clinical Oncology
15%
Neoadjuvant Therapy
15%
Evolution
15%
Consultation
15%
Tumor Biopsy
15%
Radiation Oncology
15%
Abdominal Cancer
15%
Gut Microbiota
15%
Cancer Therapy
15%
Treatment Effect
15%
Lenvatinib
15%
Bowel Obstruction
15%
Radiation Toxicity
15%
Adjuvant Chemoradiotherapy
15%
Chemoradiotherapy
15%
Phase II Trials
15%
Aflibercept
15%
Breast Cancer
15%
Dose-Volume Histogram
15%
Anal Cancer
15%
Immunotherapy
15%
Irinotecan
15%
Colon Carcinoma
15%
Colostomy
15%
Case-Control Study
15%
Carcinoma
15%
High Fiber Diet
15%
Supplementation
15%
Ipilimumab
15%
Nivolumab
15%
Keyphrases
VELOUR
15%
National Clinical Database
15%
Vanucizumab
15%
Bcl-2-associated Transcription Factor 1
15%
Symptomatic Breast Cancer
15%
Funding Information
15%
Cancer Resection
15%
MFOLFOX6
15%
Molecular Subtype Classification
15%
Transcriptional Signature
15%
Lenvatinib
15%
Complex Intervention Development
15%
Etirinotecan Pegol
15%
Complete Response Rate
15%
Post-resection
15%
Young-onset Colorectal Cancer
15%
Locally Advanced Rectal Cancer
15%
Tumor Regression Grade
15%
Gene Expression Profiling
15%
Resistance Biomarkers
15%
Perfluorooctanoate
15%
FOLFIRI
15%
HER3
15%
Pharmacokinetic-pharmacodynamic Modeling
15%
Ultra-high Risk
15%
Anal Cancer
15%
Dose-volume Histogram
15%
Preoperative Chemoradiation
15%
MEHD7945A
15%
Duligotuzumab
15%
Durvalumab
15%
Modified FOLFOX6
15%
CDKN1A
15%
Locally Advanced Colorectal Cancer
15%
RESPECT Trial
15%
Squamous Cell Carcinoma of the Anus
15%
Colostomy-free Survival
15%
Recurrent Colorectal Cancer
15%
POLD3
15%
Stage III Colorectal Cancer
15%
Intrinsic Subtype
15%
Stage II Colorectal Cancer
15%
Tumor Purity
15%
Purity Assessment
15%
Personalised Assessment
15%
Performance Status 2
12%
Whole-slide Histopathology Image
12%
Neoadjuvant Radiotherapy
10%
Life Impact
10%
Long-course Chemoradiotherapy
9%
Pharmacology, Toxicology and Pharmaceutical Science
Colorectal Carcinoma
81%
Overall Survival
50%
Neoplasm
45%
Chemotherapy
35%
Capecitabine
32%
Progression Free Survival
28%
Disease
26%
Metastatic Colorectal Cancer
24%
Malignant Neoplasm
21%
Biological Marker
20%
Chemoradiation Therapy
18%
Rectum Cancer
17%
Fluorouracil
17%
Abdominal Cancer
15%
Case-Control Study
15%
Vanucizumab
15%
Etirinotecan Pegol
15%
Squamous Cell Carcinoma
15%
Folinic Acid
15%
Mitomycin
15%
Cisplatin
15%
Aflibercept
15%
Perfluorooctanoic Acid
15%
Pharmacodynamic Modeling
15%
Duligotuzumab
15%
Pembrolizumab
15%
Anus Cancer
15%
Diflomotecan
15%
Survival Rate
8%
Cancer Mortality
7%
Coronary Artery Spasm
7%
Anus Carcinoma
6%
Adverse Event
5%
Disease Specific Survival
5%
Hand Foot Syndrome
5%
